Nabla Bio's latest AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few months.

The project could eventually add more than 400 manufacturing jobs and over 1,500 construction jobs during site development.

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a rulemaking plan to impose MFN pricing" if no “significant” progress has been made.

Ansa is accepting orders for synthetic DNA constructs ranging from 7.5 kb up to 50 kb for various applications.

Researchers use generative AI to design synthetic enhancers that can effectively control gene expression in healthy mammalian ...

The virus likely reached humans not via bat migration but through the wildlife trade—contradicting hypotheses that it may ...

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...

Researchers expect LICONN technology will be broadly useful to enable high-resolution tissue analysis in other organs and ...

To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...

From connectors and containers to plasmids and platforms, companies work to get these treatments to patients faster and more ...

Astraveus' technology possesses the ability to simultaneously decrease manufacturing costs while increasing process ...